---
title: "Weekly Recap | Legend Biotech +4.27%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302952556.md"
description: "Legend Biotech (LEGN) rose 4.27% this week to close at $19.27, while the S&P 500 slipped 0.47%, putting the stock roughly 4.74 percentage points ahead of the broader market. The week was choppy: Monday (19 Oct) opened lower, dipped to $17.995, then recovered to $18.65. Tuesday touched a high of $19.15, Wednesday pulled back to $18.63, Thursday drifted sideways, and Friday pushed back up to close near the week’s high at $19.27."
datetime: "2026-10-24T06:36:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302952556.md)
  - [en](https://longbridge.com/en/news/302952556.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302952556.md)
generator: "portal-rs"
---

# Weekly Recap | Legend Biotech +4.27%, consensus target above spot

## The Week

Legend Biotech (LEGN) rose 4.27% this week to close at $19.27, while the S&P 500 slipped 0.47%, putting the stock roughly 4.74 percentage points ahead of the broader market. The week was choppy: Monday (19 Oct) opened lower, dipped to $17.995, then recovered to $18.65. Tuesday touched a high of $19.15, Wednesday pulled back to $18.63, Thursday drifted sideways, and Friday pushed back up to close near the week’s high at $19.27. There was no major catalyst this week, with weekly amplitude around 6.98% and relatively thin turnover.

## Analyst Ratings

Among 13 brokers covering Legend Biotech, 8 rate it buy or overweight, while 5 rate it hold; none rate it underweight or sell. The consensus rating is buy, with a consensus target of $45.62231, about 136.75% above the current price of $19.27. The target range is wide, from $24.00 to $68.00, reflecting clear disagreement about the upside. Legend Biotech ranks 90th by analyst rating within the biotechnology industry, out of 511 companies.

## The Week Ahead

Macro data is heavy next week: on Tuesday (27 Oct), the US reports durable goods orders, new home sales, consumer confidence, and FHFA and Case Shiller home price indices. Softer prints could weigh on high-multiple sectors like biotech. More importantly, Legend Biotech’s Q3 FY2026 earnings are scheduled for Thursday, 12 Nov, with estimates at $0.0118 EPS and $360m revenue, offering a key checkpoint after this quiet stretch.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md)

## Related News & Research

- [What Is Drawing Attention To Legend Biotech (LEGN)?](https://longbridge.com/en/news/302964375.md)
- [Legend Biotech Stock Clears Key FDA Hurdle With LB2501 IND Approval](https://longbridge.com/en/news/302196684.md)
- [FDA Clears Legend Biotech's LB2501 CAR-T Therapy for Clinical Trials](https://longbridge.com/en/news/301974571.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [RBC Capital Sticks to Its Buy Rating for Legend Biotech (LEGN)](https://longbridge.com/en/news/298668225.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**